{"id":153635,"date":"2020-12-31T01:52:54","date_gmt":"2020-12-31T06:52:54","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/ascendis-pharma-a-s-announces-filing-of-investigational-new-drug-application-to-initiate-transcon-tlr7-8-agonist-clinical-program\/"},"modified":"2024-08-18T11:42:41","modified_gmt":"2024-08-18T15:42:41","slug":"ascendis-pharma-a-s-announces-filing-of-investigational-new-drug-application-to-initiate-transcon-tlr7-8-agonist-clinical-program","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/ascendis-pharma-a-s-announces-filing-of-investigational-new-drug-application-to-initiate-transcon-tlr7-8-agonist-clinical-program.php","title":{"rendered":"Ascendis Pharma A\/S Announces Filing of Investigational New Drug Application to Initiate TransCon\u2122 TLR7\/8 Agonist Clinical Program"},"content":{"rendered":"<p><![CDATA[-  TransCon TLR7\/8 Agonist is designed for intratumoral, sustained release of resiquimod with minimal systemic exposure, while inducing a potent anti-tumor response\u00a0-]]><\/p>\n<p>View post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/12\/30\/2151877\/0\/en\/Ascendis-Pharma-A-S-Announces-Filing-of-Investigational-New-Drug-Application-to-Initiate-TransCon-TLR7-8-Agonist-Clinical-Program.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Ascendis Pharma A\/S Announces Filing of Investigational New Drug Application to Initiate TransCon\u2122 TLR7\/8 Agonist Clinical Program\">Ascendis Pharma A\/S Announces Filing of Investigational New Drug Application to Initiate TransCon\u2122 TLR7\/8 Agonist Clinical Program<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>View post: Ascendis Pharma A\/S Announces Filing of Investigational New Drug Application to Initiate TransCon\u2122 TLR7\/8 Agonist Clinical Program <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/ascendis-pharma-a-s-announces-filing-of-investigational-new-drug-application-to-initiate-transcon-tlr7-8-agonist-clinical-program.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-153635","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/153635"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=153635"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/153635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=153635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=153635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=153635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}